44.3 Acute Non-Headache Pain Management Strategies

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

44.3 Acute Non-Headache Pain Management Strategies

Key Takeaways Explain This Topic AI

Multimodal analgesia combining non-opioid pharmacotherapies (scheduled acetaminophen, oral or topical NSAIDs) with non-pharmacologic interventions constitutes the first-line standard of care for acute somatic, visceral, and musculoskeletal pain.

Acetaminophen is dosed up to a maximum of 3,000-4,000 mg/day; NSAIDs must be used at the lowest effective dose for the shortest duration with careful assessment of renal toxicity (prerenal AKI via inhibition of vasodilatory prostaglandins), cardiovascular risk, and GI ulceration (requiring PPI co-prescription in high-risk patients); ketorolac is strictly capped at a maximum of 5 days.

Topical NSAIDs (diclofenac 1% gel) demonstrate equivalent analgesic efficacy to oral NSAIDs for acute superficial strains, sprains, and knee osteoarthritis with significantly lower systemic absorption (<5-10%) and minimal GI/renal adverse events.

Skeletal muscle relaxants (cyclobenzaprine, tizanidine, methocarbamol) act via non-specific central nervous system depression rather than direct muscle relaxation; they should be restricted to short-term courses (<=2-3 weeks) for acute muscle spasm and avoided in older adults due to Beers criteria sedation and fall risks.

The CDC Clinical Practice Guideline for Prescribing Opioids mandates that if opioids are required for severe acute traumatic or post-surgical pain, clinicians must prescribe immediate-release formulations at the lowest effective dose for no longer than the expected duration of severe pain (<=3 to 7 days; never extended-release/long-acting), verify the state Prescription Drug Monitoring Program (PDMP), and co-prescribe naloxone when overdose risk factors exist (MME >=50, concurrent benzodiazepines, history of substance use disorder).

Last updated: September 2026

The Multimodal Analgesic Framework in Primary Care

Acute pain is defined as pain of sudden onset resulting from tissue trauma, musculoskeletal strain, surgical intervention, or acute inflammation with an anticipated duration of fewer than 1 to 3 months . The historical approach of relying predominantly on escalating doses of opioid monotherapy has been replaced by the multimodal analgesic paradigm .

Core Principles of Multimodal Analgesia

Mechanistic Synergy : Pain signaling involves multiple distinct neurophysiologic phases—transduction at peripheral nociceptors, transmission along primary afferents, spinal cord dorsal horn modulation, and perception within the cerebral cortex. Multimodal analgesia combines two or more analgesic agents or modalities that act via different mechanisms and anatomical targets .

Dose Optimization & Toxicological Sparing : Combining synergistic non-opioid classes allows lower effective doses of each individual agent, maximizing analgesia while minimizing class-specific toxicities (e.g., lower NSAID doses reducing GI/renal toxicity).

Opioid Sparing : The primary goal is to achieve effective functional pain relief while minimizing or eliminating the requirement for opioid analgesics , thereby reducing opioid-induced adverse effects (sedation, nausea, respiratory depression, constipation, delirium) and mitigating the catastrophic risks of long-term dependence, tolerance, and misuse.

Non-Opioid Systemic Pharmacotherapies: Acetaminophen & NSAIDs

Non-opioid systemic medications form the mandatory first-line foundation for acute mild-to-moderate somatic, visceral, and musculoskeletal pain. SYSTEMIC NON-OPIOID ANALGESIC SPECTRUM

Agent / Class Usual Adult Dosing Mechanism of Action Key Precautions & Black Box Warnings
═══════════════════════════════════════════════════════════════════════════════════════════════════════════
Acetaminophen 500 to 1,000 mg PO q4-6h prn; Central COX inhibition; Max 3,000 mg/day (outpatients);
(Paracetamol) Max 3,000-4,000 mg/day endocannabinoid path Max 2,000 mg/day (alcoholism/hepatic);
NAPQI hepatotoxicity (antidote: NAC)

Ibuprofen 400 to 800 mg PO TID-QID Non-selective COX-1/2 Prerenal AKI (afferent constriction);
(Non-selective) (Max 2,400 to 3,200 mg/day) inhibition GI ulceration/bleeding; CV risk

Naproxen 250 to 500 mg PO BID Non-selective COX-1/2 Preferred CV profile among non-selectives;
(Non-selective) (Max 1,000 to 1,250 mg/day) inhibition Prerenal AKI; Co-prescribe PPI if GI risk

Celecoxib 100 to 200 mg PO BID or Selective COX-2 Lower GI ulceration risk; does NOT
(COX-2 Selective) 400 mg load then 200 mg BID inhibition eliminate renal toxicity; CV thrombotic risk

Ketorolac 15 to 30 mg IV/IM q6h prn; Potent non-selective BLACK BOX WARNING: Max duration STRICTLY
(Oral / Parenteral) 10 mg PO q4-6h prn COX-1/2 inhibitor 5 CONSECUTIVE DAYS (combined IV/IM/oral)
═══════════════════════════════════════════════════════════════════════════════════════════════════════════
1. Acetaminophen (Paracetamol)

Mechanism : Centrally acting analgesic and antipyretic. Inhibits central nervous system prostaglandin synthesis (COX-1, COX-2, and COX-3 variants) and modulates endogenous serotonergic and cannabinoid pathways. Crucially, it lacks significant peripheral anti-inflammatory activity.

Dosing : 500 to 1,000 mg orally every 4 to 6 hours. The recommended maximum outpatient daily dose is 3,000 mg/day (to provide a safety margin against accidental cumulative overdose from combination over-the-counter products); the absolute upper limit is 4,000 mg/day in healthy adults. In chronic alcohol dependence, cirrhosis, or malnutrition, limit to <=2,000 mg/day .

Hepatotoxicity & Metabolism : Therapeutic doses are metabolized by hepatic glucuronidation (55%) and sulfation (30%). A small fraction (~5-10%) is metabolized by cytochrome P450 CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI) , a highly reactive, toxic electrophile that is rapidly detoxified by binding hepatic glutathione . In acute overdose (>7.5-10 g) or glutathione depletion (starvation, chronic alcoholism), unneutralized NAPQI binds covalently to hepatocyte macromolecules, causing centrilobular hepatic necrosis. Antidote: N-acetylcysteine (NAC) , which replenishes glutathione.

2. Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism : Inhibit cyclooxygenase enzymes (COX-1 and/or COX-2), halting the conversion of arachidonic acid to pro-inflammatory prostaglandins (PGE2, PGI2) and thromboxanes.

The 5-Day Ketorolac Rule :

Warning

BLACK BOX WARNING: KETOROLAC 5-DAY MAXIMUM LIMIT Ketorolac is indicated exclusively for the short-term (up to 5 consecutive days ) management of moderately severe acute pain requiring opioid-level analgesia. The cumulative combined duration of IV, IM, and oral ketorolac MUST NEVER EXCEED 5 DAYS . Exceeding 5 days dramatically increases the incidence of catastrophic acute renal failure, peptic ulcer perforation, gastrointestinal hemorrhage, and life-threatening operative site bleeding.

Organ-Specific NSAID Toxicities & "The Triple Whammy"

Renal Toxicity (Afferent Arteriolar Vasoconstriction) :

Physiology : Renal prostaglandins (PGE2, PGI2) maintain afferent arteriolar vasodilation, preserving renal blood flow and glomerular capillary filtration pressure in states of reduced effective arterial volume.

Mechanism : NSAIDs block prostaglandin synthesis, leading to intense afferent arteriolar vasoconstriction and precipitously dropping GFR, causing prerenal acute kidney injury.

The "Triple Whammy" Hazard : The concurrent administration of an NSAID (afferent arteriolar vasoconstriction) + an ACE Inhibitor or ARB (inhibits angiotensin II, causing efferent arteriolar vasodilation) + a Diuretic (induces plasma volume depletion) creates a catastrophic drop in intraglomerular filtration pressure, triggering severe acute tubular necrosis and acute kidney injury!

Gastrointestinal Toxicity :

COX-1 inhibition suppresses gastric mucosal prostaglandins, impairing bicarbonate secretion, decreasing mucosal blood flow, and promoting peptic ulceration and GI bleeding. High-risk patients (age >=65, history of PUD or GI bleed, concurrent anticoagulants, antiplatelets, or systemic corticosteroids) requiring NSAIDs must receive co-prescription of a proton pump inhibitor (PPI, e.g., omeprazole 20 mg daily) or be treated with a COX-2 selective inhibitor (celecoxib) plus PPI.

Cardiovascular Thrombotic Toxicity :

Selective and non-selective NSAIDs (except possibly low-dose aspirin) increase the risk of myocardial infarction, stroke, new-onset hypertension, and congestive heart failure exacerbation by suppressing endothelial prostacyclin (a vasodilator and platelet inhibitor) relative to platelet thromboxane A2. All NSAIDs are contraindicated in the perioperative period following coronary artery bypass graft (CABG) surgery and in decompensated heart failure.

Topical Analgesic Therapies: High Efficacy with Minimal Systemic Risk

Topical analgesics provide targeted local pain relief with negligible systemic drug exposure, making them ideal first-line options in older adults, patients with renal or gastrointestinal comorbidities, or those with localized musculoskeletal injuries.

1. Topical NSAIDs: Diclofenac 1% Gel

Pharmacokinetics : Applied topically to intact skin over painful joints or muscles (2 g for upper extremity joints; 4 g for lower extremity joints up to 4 times daily). Systemic plasma concentrations of diclofenac are less than 5% to 10% of those achieved with standard oral dosing.

Clinical Efficacy : Randomized clinical trials demonstrate that topical diclofenac achieves analgesic efficacy equivalent to oral NSAIDs for acute superficial ankle sprains, muscle strains, and localized knee osteoarthritis.

Safety : Virtually eliminates the systemic gastrointestinal ulceration and prerenal nephrotoxicity associated with oral NSAIDs. Most common adverse effect is mild, localized application-site dermatitis (<5%).

2. Topical Lidocaine 5% Patch

Mechanism : Reversibly blocks voltage-gated sodium channels in cutaneous sensory nociceptors, dampening peripheral ectopic discharges and reducing secondary central sensitization.

Dosing & Administration Protocol : Apply up to a maximum of 3 patches simultaneously to intact, non-broken skin over the most painful area. Patches must be worn for a maximum of 12 hours per 24-hour period (12 hours ON, 12 hours OFF) to prevent local dermal tachyphylaxis and avoid systemic sodium channel accumulation/cardiotoxicity.

Indications : Acute herpes zoster (shingles), localized acute neuropathic pain, rib contusions, and post-herpetic neuralgia.

3. Topical Capsaicin

Mechanism : Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist. Initial application stimulates TRPV1 on unmyelinated C-fibers, causing local burning; repeated application leads to persistent desensitization and depletion of Substance P from peripheral nociceptors.

Administration : Low-concentration cream (0.025% to 0.075%) applied 3 to 4 times daily for 2 to 4 weeks. Patients must be counseled that 1 to 2 weeks of continuous use is required before significant pain relief occurs, and hand hygiene is essential to prevent accidental conjunctival contact.

Centrally Acting Skeletal Muscle Relaxants (Antispasmodics)

Skeletal muscle relaxants are widely prescribed for acute musculoskeletal conditions (e.g., acute cervical or lumbar strain). However, primary care clinicians must understand their pharmacology and clinical limitations.

Mechanism of Action: The Sedation Reality

Despite their name, centrally acting muscle relaxants exert NO direct action on the contractile mechanism of striated skeletal muscle ! Instead, their therapeutic benefit derives from non-specific central nervous system depression , polysynaptic spinal reflex inhibition, and sedation. SKELETAL MUSCLE RELAXANTS COMPARISON

Medication Usual Dosing Primary Mechanism & Properties High-Yield Clinical Pearls & Hazards
═══════════════════════════════════════════════════════════════════════════════════════════════════════════
Cyclobenzaprine 5 to 10 mg PO TID prn Structurally related to tricyclic Anticholinergic effects (dry mouth,
(or 5 mg at bedtime) antidepressants (TCAs); 5HT2 agonist confusion, urinary retention, QTc delay);
Beers Criteria: AVOID in older adults

Methocarbamol 500 to 1,000 mg PO TID-QID General CNS depression; Less sedating than cyclobenzaprine;
(Max 4,000 to 6,000 mg/day) polysynaptic reflex inhibition causes black/brown/green urine discoloration

Tizanidine 2 to 4 mg PO TID prn Central alpha-2 adrenergic agonist; Severe sedation, hypotension, dry mouth;
(Max 36 mg/day) reduces spinal interneuron outflow CONTRAINDICATED with CYP1A2 inhibitors
(ciprofloxacin, fluvoxamine)

Carisoprodol 250 to 350 mg PO TID Schedule IV Controlled Substance; METABOLIZED TO MEPROBAMATE (barbiturate-like);

(Soma) Metabolized to meprobamate HIGH ADDICTION & ABUSE RISK; STRONGLY AVOID
═══════════════════════════════════════════════════════════════════════════════════════════════════════════
Clinical Rules for Prescribing Muscle Relaxants

Short-Term Duration Only : Restrict use to a maximum of 2 to 3 weeks for acute painful muscle spasm. They have no established efficacy in chronic musculoskeletal pain.

The American Geriatrics Society (AGS) Beers Criteria Contraindication :

Muscle relaxants are categorized as potentially inappropriate medications in older adults (aged >=65 years) .

Their potent anticholinergic toxicity and central sedation cause marked cognitive impairment, acute delirium, urinary retention (especially in men with BPH), and dramatically increase the risk of falls and hip fractures in elderly patients.

Neuropathic Pharmacotherapies in Acute Pain Settings

While gabapentinoids are traditionally considered chronic neuropathic agents, they have important, evidence-based indications in specific acute pain contexts:

Gabapentin & Pregabalin (Calcium Channel Alpha-2-Delta Ligands)

Mechanism : Bind high-affinity α2δ-1 auxiliary subunits of presynaptic voltage-gated calcium channels in the dorsal horn of the spinal cord, decreasing calcium influx into presynaptic terminals and attenuating the exocytosis of excitatory neurotransmitters (glutamate, substance P, calcitonin gene-related peptide).

Indications in Acute Settings :

Acute Herpes Zoster (Shingles) : Early initiation reduces acute neuropathic allodynia and significantly decreases the incidence of transition to chronic post-herpetic neuralgia (PHN).

Acute Compressive Radiculopathy (Sciatica) : Short-term adjunctive therapy when severe lancinating, burning radicular pain persists despite NSAID therapy.

Acute Post-Surgical Neuropathic Pain : Component of perioperative multimodal protocols to reduce acute opioid requirements.

Pharmacokinetics & Dosing :

Gabapentin: Titrated from 100 to 300 mg at bedtime up to 900 to 1,800 mg/day divided TID.

Pregabalin: 50 to 75 mg BID up to 300 mg/day.

Renal Clearance : Both agents are eliminated 100% unchanged by the kidneys . Doses MUST be adjusted based on creatinine clearance (eGFR <60 mL/min) to avoid severe neurotoxicity.

Adverse Effects & Abuse Potential : Dizziness, somnolence, ataxia, and peripheral edema. Concurrent use with opioids creates synergistic central nervous system depression, substantially increasing the risk of fatal respiratory arrest .

The CDC Clinical Practice Guideline for Prescribing Opioids for Acute Pain

The updated Centers for Disease Control and Prevention (CDC) Clinical Practice Guideline for Prescribing Opioids for Pain provides strict, evidence-based recommendations for outpatient primary care clinicians managing acute non-headache pain.

The Core CDC Principles for Acute Pain CDC OPIOID PRESCRIBING RULES: ACUTE PAIN

Principle CDC Clinical Recommendation
═════════════════════════════════════════════════════════════════════════════════════════
First-Line Therapy Non-opioid pharmacotherapies (acetaminophen, NSAIDs) and non-

pharmacologic therapies are PREFERRED over opioids for acute pain.

Opioid Selection When opioids are required for severe acute pain: Prescribe

IMMEDIATE-RELEASE (IR) opioids at the lowest effective dosage.

(e.g., oxycodone 5 mg PO q4-6h prn, hydrocodone/APAP 5/325 mg).

ABSOLUTE NEVER prescribe Extended-Release / Long-Acting (ER/LA) opioids
CONTRAINDICATION (transdermal fentanyl, OxyContin, MS Contin, methadone) for acute

pain, opioid-naïve patients, or as-needed (prn) use!

Duration of Therapy Prescribe no greater quantity than needed for the expected duration

of severe pain: <=3 DAYS IS OFTEN SUFFICIENT; rarely >7 days.

PDMP Verification Check the state Prescription Drug Monitoring Program (PDMP) prior to

prescribing opioids to identify overlapping controlled substances.

Naloxone Co-prescribe Naloxone (4 mg nasal spray) if overdose risk factors

Co-Prescribing exist: MME >=50/day, concurrent benzodiazepine, history of SUD.

═════════════════════════════════════════════════════════════════════════════════════════
1. Duration of Therapy: The 3-to-7 Day Rule

Epidemiological studies demonstrate that the probability of long-term opioid dependence increases sharply with each additional day of opioid therapy beyond the third day. Prescribing an opioid supply for 3 days or fewer is often sufficient for acute severe pain (such as acute traumatic fractures or major dental extractions); a duration of more than 7 days is rarely indicated in primary care.

2. The Absolute Ban on ER/LA Opioids for Acute Pain

Caution

BLACK BOX WARNING: NEVER USE ER/LA OPIOIDS FOR ACUTE PAIN Extended-release and long-acting (ER/LA) opioids—including transdermal fentanyl patches, extended-release oxycodone, extended-release morphine, and methadone—are strictly indicated ONLY for chronic, opioid-tolerant patients requiring around-the-clock analgesia.

Prescribing an ER/LA opioid or a transdermal fentanyl patch to an opioid-naïve patient for acute pain carries an extreme, black-box risk of fatal respiratory depression and accidental death . Fentanyl patches continue delivering potent opioid medication for 24 to 48 hours even after patch removal due to subcutaneous dermal depot formation.

Risk Mitigation Strategies & Naloxone Co-Prescribing

When acute opioid therapy is deemed clinically necessary for severe trauma or post-surgical pain, clinicians must implement structured risk mitigation strategies.

1. Mandatory PDMP Review

Prior to issuing an initial prescription for any controlled substance, the clinician must query the state Prescription Drug Monitoring Program (PDMP) . The PDMP review identifies:

Undisclosed controlled substance prescriptions from other providers ("doctor shopping").

Dangerous drug-drug combinations, specifically the lethal triad of an opioid + a benzodiazepine + a muscle relaxant.

High cumulative baseline daily morphine milligram equivalents (MME).

2. Evidence-Based Indications for Co-Prescribing Naloxone

Clinicians should routinely co-prescribe intranasal Naloxone (4 mg nasal spray) and provide caregiver overdose education whenever patients have risk factors that elevate the hazard of fatal opioid-induced respiratory depression:

High Opioid Dosage : Prescriptions totaling >=50 Morphine Milligram Equivalents (MME) per day .

Concurrent Sedative Use : Concurrent prescription of benzodiazepines (e.g., lorazepam, alprazolam), non-benzodiazepine sedatives (zolpidem), or sedating muscle relaxants.

Substance Use Disorder : Personal history of alcohol use disorder, illicit substance use, or prior non-fatal overdose.

Underlying Medical Vulnerability : Severe chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), obesity hypoventilation syndrome, chronic kidney disease, or advanced hepatic failure.